Table 6 Ductal breast cancer risk in relation to high-risk haplotypes, stratified by breast cancer risk factors
From: Oestrogen receptor α gene haplotype and postmenopausal breast cancer risk: a case control study
Factor | Number, cases/controls | c.454-351A→G c.975C→G AC haplotype | c.454-397C→T c.975C→G TC haplotype | ||
|---|---|---|---|---|---|
Haplotype proportion, cases/controls | OR (95% CI)a, 1 v. 0 copiesb | Haplotype proportion, cases/controls | OR (95% CI)a, 1 v. 0 copiesb | ||
All ductal cancer cases | 1148/1511 | 0.531/0.484 | 1.19 (1.06–1.33) | 0.412/0.373 | 1.19 (1.06–1.34) |
BMI | |||||
<25 | 549/761 | 0.525/0.517 | 1.04 (0.89–1.23) | 0.404/0.388 | 1.08 (0.91–1.27) |
25-<28 | 299/429 | 0.531/0.458 | 1.32 (1.06–1.64) | 0.391/0.348 | 1.21 (0.97–1.51) |
≥ 28 | 300/321 | 0.541/0.456 | 1.41 (1.12–1.77) | 0.449/0.357 | 1.48 (1.17–1.88) |
Parity | |||||
0 | 158/134 | 0.495/0.472 | 1.14 (0.82–1.60) | 0.399/0.388 | 1.11 (0.80–1.54) |
1 | 248/258 | 0.535/0.439 | 1.43 (1.10–1.84) | 0.422/0.349 | 1.35 (1.04–1.74) |
2+ | 706/1043 | 0.535/0.496 | 1.17 (1.01–1.34) | 0.413/0.377 | 1.17 (1.02–1.35) |
Menopausal hormone treatment | |||||
<2 years | 861/1169 | 0.533/0.482 | 1.23 (1.08–1.40) | 0.416/0.374 | 1.21 (1.06–1.38) |
≥ 2 years | 251/266 | 0.515/0.490 | 1.08 (0.84–1.40) | 0.391/0.369 | 1.08 (0.84–1.40) |
Family history | |||||
No | 935/1246 | 0.528/0.486 | 1.18 (1.04–1.33) | 0.413/0.368 | 1.21 (1.07–1.30) |
Yes | 183/128 | 0.548/0.505 | 1.17 (0.84–1.63) | 0.403/0.425 | 0.93 (0.67–1.30) |
Age at menopause | |||||
≤ 49 years | 324/506 | 0.555/0.496 | 1.25 (1.02–1.54) | 0.431/0.385 | 1.25 (1.01–1.54) |
49.5–51.5 years | 445/503 | 0.511/0.470 | 1.19 (0.98–1.43) | 0.397/0.356 | 1.19 (0.98–1.45) |
≥ 52 years | 372/489 | 0.534/0.494 | 1.18 (0.97–1.44) | 0.411/0.372 | 1.17 (0.96–1.44) |